Phase I study of everolimus (RAD001) and AMG 479 in patients (pts) with advanced solid tumors and colorectal cancer (CRC).

被引：0
|
作者：
Khawaja, M. R.
Younger, A.
Funke, J. M.
Waddell, M. J.
Jones, D. R.
Pollok, K.
Prasad, N. K.
Berry, W.
Sandusky, G.
Chiorean, E. G.
机构：
[1] Indiana Univ Sch Med, Indianapolis, IN 46202 USA
[2] Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA
[3] Indiana Univ, Indianapolis, IN 46204 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS157
引用
收藏
页数：1
相关论文
共 50 条
  • [21] The oral mTOR inhibitor RAD001 (everolimus) in combination with letrozole in patients with advanced breast cancer:: Results of a phase I study with pharmacokinetics
    Awada, Ahmad
    Cardoso, Fatima
    Fontaine, Christel
    Dirix, Luc
    De Greve, Jacques
    Sotiriou, Christos
    Steinseifer, Jutta
    Wouters, Carine
    Tanaka, Chiaki
    Zoellner, Ulrike
    Tang, Pui
    Piccart, Martine
    EUROPEAN JOURNAL OF CANCER, 2008, 44 (01) : 84 - 91
  • [22] Phase I study of the combination of everolimus (RAD001) with 5FU/LV in patients with refractory solid malignancies
    Davies, J. M.
    McRee, A. J.
    Sanoff, H. K.
    Triglianos, T.
    Keller, K.
    Ivanova, A.
    Bernard, S. A.
    Goldberg, R. M.
    Dees, E. C.
    O'Neil, B. H.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (04)
  • [23] Phase I study of RAD001 (everolimus), cetuximab, and irinotecan as second-line therapy in metastatic colorectal cancer (mCRC)
    Sharma, S.
    Reid, T.
    Hoosen, S.
    Garrett, C.
    Beck, J.
    Davidson, S.
    MacKenzie, M.
    Brandt, U.
    Hecht, J.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [24] A phase I study of temozolomide (TMZ) and RAD001 in patients (pts) with glioblastoma multiforme (GBM)
    Mason, W. P.
    MacNeil, M.
    Easaw, J.
    McIntosh, L.
    Lwin, Z.
    Chen, E.
    Eisenhauer, E. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer
    Wolpin, Brian M.
    Ng, Kimmie
    Zhu, Andrew X.
    Abrams, Thomas
    Enzinger, Peter C.
    McCleary, Nadine J.
    Schrag, Deborah
    Kwak, Eunice L.
    Allen, Jill N.
    Bhargava, Pankaj
    Chan, Jennifer A.
    Goessling, Wolfram
    Blaszkowsky, Lawrence S.
    Supko, Jeffrey G.
    Elliot, Meaghan
    Sato, Kaori
    Regan, Eileen
    Meyerhardt, Jeffrey A.
    Fuchs, Charles S.
    ONCOLOGIST, 2013, 18 (04): : 377 - 378
  • [26] Activity of everolimus (RAD001) in relapsed and/or refractory multiple myeloma: a phase I study
    Guenther, Andreas
    Baumann, Philipp
    Burger, Renate
    Kellner, Christian
    Klapper, Wolfram
    Schmidmaier, Ralf
    Gramatzki, Martin
    HAEMATOLOGICA, 2015, 100 (04) : 544 - 550
  • [27] Phase Ib study of RAD001 (R) with pegylated-liposomal doxorubicin (PLD) in patients with advanced solid tumors
    Perotti, A.
    Sessa, C.
    Colombo, N.
    Del Conte, G.
    Delmonte, A.
    Diena, T.
    Lapresa, M.
    Parma, G.
    Vigano, L.
    Gianni, L.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [28] Randomized, phase I, and pharmacokinetic (PK) study of RAD001, an mTOR inhibitor, in patients (pts) with advanced hepatocellular carcinoma (HCC)
    Chen, L.
    Shiah, H. S.
    Chen, C. Y.
    Lin, Y. J.
    Lin, P. W.
    Su, W. C.
    Chang, J. Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [29] Phase I trial of gemcitabine and split-dose cisplatin plus everolimus (RAD001) in patients with advanced urothelial cancer.
    Abida, Wassim
    Milowsky, Matthew I.
    Ostrovnaya, Irina
    Gerst, Scott R.
    Rosenberg, Jonathan E.
    Regazzi, Ashley Marie
    McCoy, Asia S.
    Boyd, Mariel Elena
    Bajorin, Dean F.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (07)
  • [30] Phase I trial of capecitabine plus everolimus (RAD001) in patients with previously treated metastatic gastric cancer
    Lim, Taekyu
    Lee, Jeeyun
    Lee, Duk Joo
    Lee, Ha Yeon
    Han, Boram
    Baek, Kyung Kee
    Ahn, Hee Kyung
    Lee, Su Jin
    Park, Se Hoon
    Park, Joon Oh
    Park, Young Suk
    Lim, Ho Yeong
    Kim, Kyoung-Mee
    Kang, Won Ki
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2011, 68 (01) : 255 - 262
12345